Dr Paul Jourdan: "Lots of people love to knock Aim. I'm absolutely not in that camp"
Paul Jourdan, CEO of Amati Global Investors, tells Christopher Akers why he thinks the Alternative Investment Market is an asset of national importance and shares his thoughts on overpricing in "the year of IPOs". He explains Amati's approach to ESG and discusses the stocks that have been important for them over the…
We score an episode from what we can actually measure — its reach and engagement, what listeners say about it, and what it covers. We don't have those signals for this one yet, so it doesn't get a number.
Buzzmeter says it's buzzing across platforms — the Hive Vote says whether the people who actually listened liked it.
Rate this episode
Add your vote to the Hive — listeners rate every episode after they finish.
- No reviews yet — be the first.
Similar episodes from other shows
More like Investors' Chronicle →
Dr Paul Jourdan: strategic metals, the commodities supercycle and the electrified future
The fund manager who got out before China sell-off, a defence company with a hidden jewel, and the junior bankers’ struggle for a big payday
Adrian Frost: Why flexible UK Equity Income strategies work for patient investors | #12
Is the tide starting to turn for UK smaller companies?
One great episode in your inbox, daily — free.
One email a day, unsubscribe anytime. No spam, ever.